abstract |
The present invention relates to a novel C-terminal exon of RUNX1/AML1, its nucleic acid sequence, its peptide and a full length amino acid sequence comprising the novel C-terminal exon. Furthermore, the invention is directed to an antibody against the C-terminal exon of RUNX1/AML1, a pharmaceutical composition for the treatment of various diseases, among others various tumours and the use of the C-terminal exon for the manufacture of a medicament. The C-terminal exon may also be used for the inhibition of cellular growth and/or induction of apoptosis. Furthermore, the invention relates to a method and a kit for diagnosing a disease, both using the C-terminal exon. |